MOMIPP

MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB) [1][2].

Product Specifications

CAS Number

[1363421-46-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PIKfyve

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/momipp.html

Purity

99.00

Solubility

DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(/C=C/C1=C(NC2=C1C=C(C=C2)OC)C)C3=CC=NC=C3

Molecular Formula

C18H16N2O2

Molecular Weight

292.33

Precautions

H302, H315, H319, H335

References & Citations

[1]Margaux Colin, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide. Cancers (Basel) . 2019 Mar 22;11 (3) :411.|[2]Zehui Li, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019 Jan 16;19 (1) :77.